Thursday, 15 October 2026European Markets

ALMUNDA PRO NV Stock Went Up By Over 15% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of ALMUNDA PRO NV (AEX-Index: AMUND.AS) rose by a staggering 15.08% in 5 sessions from €1.26 to €1.45 at 14:16 EST on Tuesday, following the last session's downward trend. AEX-Index is jumping 0.71% to €763.82, after four sequential sessions in a row of gains.

ALMUNDA PRO NV's last close was €1.45, 5.84% under its 52-week high of €1.54.

About ALMUNDA PRO NV

Almunda Professionals N.V., a business and IT consultancy company, provides business services in the financial sector. It offers consultancy services in the areas of regulatory change, digital transformation, information security, and information services. The company was formerly known as Novisource N.V. and changed its name to Almunda Professionals N.V. in August 2021. Almunda Professionals N.V. was founded in 2001 and is based in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, ALMUNDA PRO NV has a trailing twelve months EPS of €0.08.

PE Ratio

ALMUNDA PRO NV has a trailing twelve months price to earnings ratio of 18.13. Meaning, the purchaser of the share is investing €18.13 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.86%.

More news about ALMUNDA PRO NV (AMUND.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com